A key event in the development of both major forms of diabetes is the loss of functional 37
Introduction

58
Both major forms of diabetes involve loss of functional -cell mass, but methods for 59 reliably inducing human -cell proliferation with full retention of key functions such as glucose-60 stimulated insulin secretion (GSIS) are still very limited. Early approaches focused on 61 manipulation of oncogenes or core elements of the cell replication machinery such as cyclin 62 D1, cdk6, p16 or p57 [1] [2] [3] , but such strategies either led to functional impairment or were not 63 therapeutically tractable due to the common use of these factors for cell cycle control in all 64 tissues in the body. More recently, several groups reported that inhibition of the tyrosine 3 68 systemic administration of harmine activates islet -, -, and ductal cell proliferation in addition 69 to its effects on -cells [5] . Therefore, additional strategies for expansion of functional human 70 -cell mass are needed, including mechanisms that are orthogonal to the Dyrk1A/NFAT 71 pathway.
73
Our laboratory has performed a series of studies on overexpression of the homeobox 74 transcription factor Nkx6.1 in pancreatic islets [7] [8] [9] [10] [11] [12] . Key findings include: 1)
75
Overexpression of Nkx6.1 in rat islets results in increased -cell replication accompanied by 76 improved GSIS [7, 8] ; 2) Nkx6.1 induces expression of a prohormone, VGF, in both rat and 77 human islets, which is processed to yield multiple peptides, including TLQP-21 [9] . TLQP-21
78 protects -cells from apoptotic cell death, and VGF plays an important role in insulin vesicle 79 trafficking [9, 12] . However, VGF or its peptides do not activate -cell proliferation [9] ; 3) 143 Glucose-Stimulated Insulin Secretion. Human islets were pretreated with 10 µM GNF-9228 144 or DMSO for 72h. Insulin secretion was measured by static incubation of 30 islets in 4 145 replicate groups as previously described [9] . Secreted insulin was measured by ELISA (80-
146
INSMR-CH10, ALPCO) and normalized to insulin content [9] . To measure the acute effects of 147 GNF-9228, some batches of human islets were treated with GNF-9228 during the secretion 148 assay only (no pre-treatment).
149
Viability and cell toxicity assays. 832/13 cells were seeded in 96-well tissue culture dishes.
150
To induce cell toxicity, cells were treated with 200-500 nM thapsigargin or with a mixture of 1 7 151 ng/ml rat IL-1 (Sigma) + 100 U/ml rat IFN- (Thermo) . Cell viability was measured using the 
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The counterscreening protocol yielded 41 compounds with activity profiles similar to those 187 shown for compounds GNF-9228 and GNF-7169, featuring robust, dose-dependent activation 188 of the VGF-luc construct, with no activation of PLTP-luc (Fig 1) . Since the VGF promoter 189 contains a consensus cyclic AMP response element-binding protein (CREB) binding 190 sequence [17], compounds were also counterscreened against a CREB-luc reporter.
191
Compound GNF-7169 had no activity against the CREB-luc construct, whereas GNF-9228 192 had a weak activating effect (Fig 1) . 
199
Dose response curves for two representative hits, GNF-7169 and GNF-9228, are shown.
201
We studied the effects of the 41 lead compounds on islet cell proliferation, GSIS, and 202 protection against apoptotic cell stress. Through this, we isolated three compounds (GNF-9 203 9228, GNF-1346, and GNF-4088) with robust and consistent effects to stimulate human islet 204 cell proliferation. GNF-9228 and GNF-4088 are variants of a common chemotype, whereas
205
GNF-1346 has a distinct structure (Fig 2A) . Consistent with the design of the screen, both 206 GNF-9228 and GNF-1346 caused potent induction of Nkx6.1 mRNA expression in 832/13 207 cells (Fig 2B) . However, when tested on human islets, the two compounds caused a non-208 significant trend to increase Nkx6.1 mRNA, and had no effect on expression of VGF or the c-209 myc oncogene, a known activator of islet cell replication (Figs 2C, 2D, 2E) [18]. GNF-9228
210 was found to be the most potent of the three compounds for stimulation of human islet cell 211 proliferation, and studies that follow therefore focus on the activities of this molecule. percentages of EdU-positive islet cells, -cells, and -cells, is provided in (S1 Table) . In Table) . Taken together, these data suggest that under the conditions used in 263 264 GNF-9228 stimulates insulin secretion in rat and human islets. We next tested the 265 impact of GNF-9228 on insulin secretion. Acute (less than 24 hour exposure) of islets to 266 GNF-9228 had no impact on GSIS (S1 Fig). However, pre-exposure of human islets to 5 or 10 267 µM GNF-9228 for 72 hours caused a 75-140% increase in insulin secretion in the presence of 268 stimulatory (16.7 mM) glucose compared to human islets treated with DMSO (Fig 4) . Insulin
269
secretion was normalized to insulin content in these experiments, which showed a non-270 significant trend to decrease in response to GNF-9228 treatment (human islets treated for 72 271 h with 5 µM or 10 µM GNF-9228 had 86 ± 9.1% and 83 ± 12.9% of the insulin content 272 measured in DMSO-treated islets, respectively). This non-significant change in insulin content 273 does not explain the enhanced insulin secretion elicited by GNF-9228 treatment. We also note 274 that insulin secretion at basal (2.8 mM) glucose levels increased significantly at 5 µM, and 275 showed a non-significant trend to increase at 10 µM GNF-9228 (Fig 4) . This increase in basal 276 insulin secretion caused the stimulation index (insulin secreted at 16.7 mM relative to 2.5 mM 277 glucose) to be essentially identical in the GNF-9228 and DMSO-treated islets. Nevertheless, 278 pretreatment with, but not acute exposure to GNF-9228 enhances insulin secretion at 279 stimulatory glucose in human islets. test GNF-9228 for its potential pro-survival effects, 832/13 cells were exposed to 500 nM 292 thapsigargin (TG) for 6 hours in the presence and absence of 10 µM GNF-9228. Co-treatment 293 of 832/13 cells with TG + GNF-9228 resulted in a clear reduction in cleaved caspase-3 294 compared to control cells incubated with TG + DMSO (Figs 5A and 5B) . In another set of 295 experiments, 832/13 cells were pretreated with GNF-9228 or vehicle for 24 h followed by 24 h 296 exposure to 200 or 250 nM thapsigargin (TG) or a mixture of the cytotoxic cytokines IL-1 and 297 -IFN in the presence or absence of GNF-9228 (Fig 5C) . In these experiments, cell viability Fig) . Also indicative of a 326 unique mechanism of action, GNF-9228 caused a significant 3.9-fold increase in VGF-luc 327 activity relative to DMSO treatment (p < 0.005), whereas GNF-4877 failed to cause significant 328 luc activation in this assay (Fig 6C) . We also compared the proliferative effects of 10 µM GNF-9228 to those of 5 µM GNF-4877, a 343 concentration reported as maximally active for islet cell proliferation [4] . In these experiments 344 (Figure 7) human islets were exposed to EdU for 72 hours, in contrast to the studies in Figure   345 3 where EdU was provided for 18 hours. All 6 human islet preps responded to GNF-9228 or 346 GNF-9228 + GNF-4877 with an increase in EdU incorporation into total islet cells and -cells,
347
with statistically significant average responses of approximately 10-fold to both treatment 348 conditions (Fig 7 and S3 Table) . GNF-4877 also increased EdU incorporation into -cells in 349 all 6 human islet preps, with an average increase of 4-fold (p = 0.06). (Fig 7) . Combining the 350 two compounds had no additive effect on total cell or -cell proliferation. GNF-9228 or GNF-351 9228 + GNF-4877 also caused an average, statistically significant 5-fold increase in -cell
352
EdU incorporation in 5 separate human islet aliquots (Fig 7 and S3 Table) . GNF-4877 alone 353 also increased -cell EdU incorporation in all 5 preps surveyed, with an average 3-fold 354 increase (p = 0.06). We also measured EdU incorporation into -cells in human islet preps 355 treated with EdU for 72 hours and again found no consistent effect of GNF-9228 (S1 Table) .
356
Thus, with longer duration of EdU exposure, we find that GNF-9228 increases both -cell and 357 -cell but not -cell replication, with a preferential effect on -cells. properties of GNF-1346 and GNF-4088 were even less encouraging. Nevertheless, we 378 performed a study in which GNF-9228 was injected into C57BL6 mice daily at a dose of 30 379 mg/kg for one week, with mice receiving BrdU in the drinking water at a concentration of 0.8 380 mg/ml throughout the study. GNF-9228 treatment caused no incease in BrdU incorporation 381 into mouse islet cells compared to DMSO-treated mice, likely due to its rapid clearance.
